Table 1

Spearman correlation coefficients (and p values) between measures of disease activity and MRIa score

MRIa score
Baseline (n=221)Change from baseline to week 24 (n=158)*Change from baseline to week 102 (n=179)*
CRP
 Baseline0.28 (<0.001)−0.25 (0.002)−0.31 (<0.001)
 Change from baseline to week 24/week 1020.25 (0.002)0.32 (<0.001)
ASDAS
 Baseline0.16 (0.016)−0.14 (0.076)−0.15 (0.044)
 Change from baseline to week 24/week 1020.22 (0.006)0.23 (0.002)
BASDAI
 Baseline−0.09 (0.174)0.12 (0.132)0.14 (0.063)
 Change from baseline to week 24/week 1020.14 (0.090)0.14 (0.057)
Patient global
 Baseline−0.02 (0.759)−0.02 (0.816)0.02 (0.837)
 Change from baseline to week 24/week 1020.10 (0.196)0.12 (0.116)
BASDAI Q1—fatigue/tiredness
 Baseline−0.08 (0.216)0.08 (0.351)0.08 (0.289)
 Change from baseline to week 24/week 1020.11 (0.179)0.18 (0.015)
BASDAI Q2—axial pain
 Baseline−0.01 (0.877)−0.02 (0.716)0.01 (0.892)
 Change from baseline to week 24/week 1020.21 (0.009)0.18 (0.019)
BASDAI Q3—joint pain/swelling
 Baseline−0.18 (0.008)0.17 (0.033)0.21 (0.004)
 Change from baseline to week 24/week 1020.00 (0.976)−0.05 (0.518)
BASDAI Q4—discomfort to touch
 Baseline0.00 (0.983)0.10 (0.237)0.02 (0.797)
 Change from baseline to week 24/week 1020.06 (0.436)0.12 (0.098)
BASDAI Q5—intensity of morning stiffness
 Baseline−0.08 (0.227)0.11 (0.179)0.13 (0.078)
 Change from baseline to week 24/week 1020.10 (0.201)0.12 (0.099)
BASDAI Q6—duration of morning stiffness
 Baseline−0.05 (0.490)0.09 (0.264)0.10 (0.175)
 Change from baseline to week 24/week 1020.07 (0.380)0.11 (0.135)
BASDAI Q5/6—morning stiffness (inflammation)
 Baseline−0.08 (0.262)0.12 (0.121)0.14 (0.064)
 Change from baseline to week 24/week 1020.11 (0.171)0.14 (0.063)
  • *Data are shown for the all patients at baseline, for changes in the infliximab group at 24 weeks (placebo-controlled phase of the ASSERT trial) and for changes in all patients at 102 weeks (open extension phase of the ASSERT trial); the corresponding follow-up change score in each clinical/laboratory variable was used to calculate the correlation coefficient with MRI change scores.

  • ASDAS, ankylosing spondylitis disease activity score; ASSERT, AS Study for the Evaluation of Recombinant Infliximab Therapy; BASDAI, Bath ankylosing spondylitis disease activity index; CRP, C-reactive protein; MRIa, MRI activity; Q, question.